Home Compare BIIB vs GRF.MC
Stock Comparison · Industry comparison · Drug Manufacturers - General

Biogen vs Grifols: Which Stock Looks Stronger in 2026?

Grifols, holds the cleaner structural position, with growth as the main driver and profitability adding further support. In the market, Biogen carries the stronger setup — intact trend against Grifols,'s broken trend. That leaves a split case: the structural lead stays with Grifols,, but the market is not currently confirming it.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

Growth still does most of the heavy lifting in this comparison. The overall score gap is 9 points in favour of Grifols, S.A..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - General

This comparison is based on industry proximity, not on functional trajectory similarity. BIIB and GRF.MC share the same industry classification.

For a similarity-based comparison, see how Biogen and Grifols, each position within their functional peer groups in AssetNext.

Peer-Relative Score
BIIB
Biogen Inc.
26
Peer-Score
Signal qualityHigh
vs
GRF.MC
Grifols, S.A.
35
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: BIIB vs GRF.MC Profitability 0 11 Stability 10 10 Valuation 80 76 Growth 0 35 BIIB GRF.MC
Gap Ranking
#1 Growth +35
#2 Profitability +11
#3 Valuation +4
#4 Stability
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for BIIB and GRF.MC Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer BIIBGRF.MC Relative valuation Structural strength

The price setup looks more supportive for Grifols, S.A., but Biogen Inc. still has the stronger structure.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both sit in the weaker half on growth, with Grifols, S.A. still coming out ahead.
Profitability
Neither side looks especially strong on profitability, though Biogen Inc. still ranks somewhat higher.
Growth — Dominant Gap
BIIB
0
GRF.MC
35
Gap+35in favour of GRF.MC

One company is still expanding while the other is contracting, which creates a very wide growth split.

What keeps the gap from being one-sided

On the market side, Biogen carries the stronger trend while Grifols,'s trend has broken — the market setup does not confirm the structural advantage.

What this means for the comparison

Growth is the clearest driver, and profitability also supports Grifols, S.A.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the BIIB vs GRF.MC comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how BIIB and GRF.MC each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.